在中国从双价值型到非价值型的HPV疫苗接种计划转换的成本效益分析:一个建模研究
Meng Gao1,2,3, Shangying Hu1, Xuelian Zhao1
1Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
预计在中国转向非价值HPV疫苗可以节省成本,并显著减少子宫癌. 这种策略比目前的双价疫苗接种计划更有价值.
科学领域:
- 公共卫生 公共卫生
- 疫苗学 疫苗学 疫苗学
- 卫生经济学 卫生经济学
背景情况:
- 由于依赖海外制造业,中国面临非价值HPV疫苗供应和成本的挑战.
- 国内生产的非价值HPV疫苗候选人正在III期试验中,可能会提高可用性.
研究的目的:
- 为了比较转向中国非价值HPV疫苗接种的人口水平的有效性和成本效益.
- 评估不同的疫苗接种策略,包括同种疫苗和混合疫苗计划.
主要方法:
- 一个经过验证的传播模型被用来预测各种疫苗接种策略的终身成本和有效性.
- 该研究考虑了2023年至2100年中国的所有女性,采用了社会视角.
- 使用成本效益效率边界来确定最佳策略.
主要成果:
- 与目前的双价疫苗计划相比,切换到非价值疫苗接种始终节省了成本,净节省了1.852-52.11亿美元.
- 采用混合双价和非价疫苗计划可以进一步节省1.336-42.80亿美元,并获得8.7万-83.3万个QALY.
- 最佳策略转向从双价HPV疫苗转向非价HPV疫苗,如果2035年后可以获得非价HPV疫苗.
结论:
- 在中国,过渡到非价值HPV疫苗接种可能会节省成本.
- 这种转换预计将大大减少宫癌的负担.
- 混合疫苗接种计划提供额外的成本节省和健康益处.
更多相关视频
06:22Standardization of Transfer across Labs between Flow Cytometers for Detection of Lymphocytes in Japanese Encephalitis Vaccinated Children
Published on: February 10, 2023
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
相关概念视频
Models of Health Promotion and Illness Prevention I
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
